Literature DB >> 8667440

Deceptive prothrombin and activated partial thromboplastin times in alcoholic cirrhosis.

P R Sirikonda1, C R Spillert, B Koneru, R Ponnudurai, D J Wilson, E J Lazaro.   

Abstract

It is believed that perioperative hemorrhage, in the hepatoportal area, results from a coagulopathy. This study determined if this could be quantitated by a modified recalcification time (MRT) test developed in our laboratory. Unlike prothrombin (PT) and activated partial thromboplastin times (APTT), the MRT is performed with whole blood to ensure the role of blood cells and chemicals (particularly tissue factor, a potent procoagulant) in the coagulation process. Candidates for liver transplantation (n = 11) were studied. Samples (5 mL) of citrated venous blood were obtained from the patients. Aliquots (1 mL) from these samples were divided into groups of vials labeled C, S, and E. Groups C and S received 20 microL saline and group E, 20 microL of saline containing 10 micrograms of Escherichia coli endotoxin (055: B5W). Vial C was incubated for 10 minutes and vials S and E for 120 minutes, all at 37 degrees C. Then, the MRT was determined on 300 microL of blood from each vial after adding 40 microL of 0.1M calcium chloride. Mean MRT values (minutes +/- standard deviation) for C (MRTC), for S (MRTS), and for E (MRTE) were compared with like values from healthy controls (n = 29). Despite prolonged PT and APTT values, MRT values were shortened in patients with cirrhosis. This hypercoagulability detected by the MRT exonerates a hemorrhagic coagulopathy and possibly implicates widened and thinned gaps in the walls of the portal venous tributaries as the cause of perioperative hemorrhage.

Entities:  

Mesh:

Year:  1996        PMID: 8667440      PMCID: PMC2608053     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  13 in total

1.  Hepatic removal of activated factor X by the perfused rabbit liver.

Authors:  D Deykin; F Cochios; G DeCamp; A Lopez
Journal:  Am J Physiol       Date:  1968-02

2.  Increase in monocyte procoagulant activity with age.

Authors:  Y Calmus; A Robert
Journal:  Thromb Res       Date:  1986-01-01       Impact factor: 3.944

3.  Therapeutic options for biliary tract disease in advanced cirrhosis.

Authors:  G V Aranha; D Kruss; H B Greenlee
Journal:  Am J Surg       Date:  1988-03       Impact factor: 2.565

4.  The modified recalcification time (MRT) assesses prothrombophlebitic role of conjugated estrogen (premarin).

Authors:  H Erhard; C R Spillert; R Ponnudurai; S Bonthu; E J Lazaro
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

5.  Tissue thromboplastin activity of isolated human monocytes.

Authors:  H Prydz; A C Allison
Journal:  Thromb Haemost       Date:  1978-06-30       Impact factor: 5.249

6.  An assessment of monocyte procoagulant activity in patients with solid tumors.

Authors:  K S Dasmahapatra; N K Cheung; C Spillert; E Lazaro
Journal:  J Surg Res       Date:  1987-08       Impact factor: 2.192

7.  Deficiencies of protein C, an inhibitor of blood coagulation.

Authors:  P M Mannucci; S Vigano
Journal:  Lancet       Date:  1982-08-28       Impact factor: 79.321

8.  Monocyte procoagulant activity in breast cancer.

Authors:  M J Auger; M J Mackie
Journal:  Thromb Res       Date:  1987-07-01       Impact factor: 3.944

9.  Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation.

Authors:  R L Edwards; F R Rickles; M Cronlund
Journal:  J Lab Clin Med       Date:  1981-12

10.  Monocytes can be induced by lipopolysaccharide-triggered T lymphocytes to express functional factor VII/VIIa protease activity.

Authors:  B P Tsao; D S Fair; L K Curtiss; T S Edgington
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.